101 Therapeutics to Present Arthritis Drug Data
The company will report results from a Phase 2/3 clinical trial comparing 101-PGC-005 to dexamethasone on November 8, 2026.
Updated on Oct. 20, 2026 in Arthritis
Live Poll
Would you prefer using targeted drug therapies to avoid the side effects of traditional steroids?
101 Therapeutics is scheduled to present clinical data for its experimental drug 101-PGC-005 at the ACR Convergence 2026 meeting in Orlando on November 8, 2026. The presentation will detail findings from a 309-patient trial conducted in India comparing the compound to systemic dexamethasone.
Why it matters
Researchers are positioning 101-PGC-005 as a potential steroid-sparing adjunct to biologic therapy, which could offer a new approach for managing rheumatology indications. The company intends to further explore the drug for use in treating systemic juvenile idiopathic arthritis.
The trial reported a hazard ratio of 2.31 for clinical improvement and 1.47 for viral clearance compared to dexamethasone. Additionally, 77.4% of patients in the 101-PGC-005 arm were discharged by day 5, versus 29.0% in the control arm.
The players
101 Therapeutics
This pharmaceutical company specializes in developing targeted therapies for inflammatory and autoimmune conditions.
The details
The compound 101-PGC-005 is a CD206-targeted dexamethasone prodrug designed to deliver glucocorticoids specifically to macrophages. In the trial, patients received 20 mg of the prodrug intravenously once daily for three days, resulting in zero cumulative exogenous corticosteroid exposure.
Timeline
November 6-11, 2026: ACR Convergence 2026 meeting dates.
November 8, 2026: Poster presentation of clinical data.
Health Landscape
The presentation of 101-PGC-005 data at the ACR Convergence annual scientific meeting follows the industry standard for unveiling major rheumatology clinical trial results. This research reflects a broader scientific shift toward developing targeted prodrugs that reduce the systemic side effects typically associated with conventional steroid treatments.
Patients may eventually gain access to a treatment option designed to minimize total corticosteroid exposure through targeted drug delivery. The development aims to improve recovery speeds and reduce the side effects often experienced with traditional high-dose steroid therapies.
The takeaway
This drug candidate represents an effort to improve the safety profile of standard anti-inflammatory medications. Patients and providers should watch for upcoming study results that may confirm its efficacy for long-term chronic condition management.
What happens next
101 Therapeutics is planning a future study for 101-PGC-005 in systemic juvenile idiopathic arthritis, though specific start dates have not been finalized.
Further reading
For more information on current treatment developments, visit the Arthritis section.
Live Poll
Would you prefer using targeted drug therapies to avoid the side effects of traditional steroids?
